Stammdaten
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Unternehmen & Branche
| Name | Estrella Immunopharma, Inc. |
|---|---|
| Ticker | ESLA |
| CIK | 0001844417 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 62,7 Mio. USD |
| Beta | 0,58 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -13,063,512 | -0.35 | 3,176,975 | -10,366,058 | |
| 2025-09-30 | 10-Q | -4,801,149 | -0.13 | 3,523,511 | -9,836,423 | |
| 2025-06-30 | 10-Q | -5,544,878 | -0.15 | 2,980,527 | -6,094,668 | |
| 2025-03-31 | 10-Q | -2,104,311 | -0.06 | 2,444,268 | -1,830,947 | |
| 2024-12-31 | 10-K | -4,427,027 | -0.12 | 3,140,777 | 143,731 | |
| 2024-09-30 | 10-Q | -3,376,737 | -0.09 | 3,735,145 | 746,286 | |
| 2024-06-30 | 10-Q | -3,951,072 | -0.11 | 4,454,189 | 4,273,488 | |
| 2024-06-30 | 10-K | -7,311,723 | -0.27 | 4,454,189 | 4,273,488 | |
| 2024-03-31 | 10-Q | -469,530 | -0.01 | 8,633,400 | 8,494,909 | |
| 2023-12-31 | 10-Q | -1,020,624 | -0.03 | 9,447,263 | 9,048,530 | |
| 2023-09-30 | 10-Q | -1,870,497 | -1.78 | 27,349,707 | 10,069,154 | |
| 2023-06-30 | 10-K | -11,114,402 | -36.35 | 3,028,399 | -11,742,550 | |
| 2023-06-30 | 10-Q | -76,004 | 3,028,399 | -11,742,550 | ||
| 2023-03-31 | 10-Q | -2,741,106 | -8.13 | 9,781,282 | -9,113,961 | |
| 2022-12-31 | 10-Q | -2,756,340 | -16.33 | 9,723,802 | -6,475,779 | |
| 2022-12-31 | 10-K | -996,104 | 9,723,802 | -2,255,685 | ||
| 2022-09-30 | 10-Q | -2,885,444 | -34.33 | 45,620,361 | -3,822,363 | |
| 2022-06-30 | 10-Q | -359,586 | -0.06 | 45,384,117 | -1,039,843 | |
| 2022-03-31 | 10-Q | -141,252 | -0.02 | 45,619,256 | -1,147,444 | |
| 2021-12-31 | 10-K | -247,718 | 45,803,462 | -1,006,192 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-10-07 | Xu Jiandong | Officer, Chief Financial Officer | Open Market Purchase | 1,000 | 1.33 | 1,330.00 | +153,8% | |
| 2025-09-22 | Xu Jiandong | Officer, Chief Financial Officer | Open Market Purchase | 1,000 | 1.16 | 1,160.00 | +134,2% | |
| 2025-09-11 | Xu Jiandong | Officer, Chief Financial Officer | Open Market Purchase | 100 | 1.04 | 104.00 | +12,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.